Niarmedic

NIARMEDIK is a Russian medical, innovative, biotechnology and pharmaceutical company. The main task of the office is to coordinate and manage the work of all clinics and warehouses that are part of the NIARMEDIC network.

Limited Liability Company "NIARMEDIC PLUS" - Russian pharmaceutical, biotechnological, medical company was created in 1989 by like-minded scientists of the Research Institute of Epidemiology and Microbiology named after N.F. Gamalei to introduce the results of his own scientific research and development into wide medical practice in various fields of laboratory diagnostics, immunology, infectology and other areas. The company produces diagnostic test systems, original pharmaceuticals, including the antiviral drug KAGOCEL and the COLLOST reducing complex. It supplies laboratory equipment manufactured by the world's leading manufacturers to the domestic market, conducts its service, and also develops a network of multidisciplinary clinics for the provision of comprehensive medical care. Today, NIARMEDIC PLUS is one of the TOP-10 of the best innovative companies in Russia that actively use biotechnology in medicine. General Director and Founder of the company, Doctor of Medical Sciences, Professor Vladimir Nesterenko.

History

2025

ABC-Medicine bought 100% of the Niarmedic network

In December 2025, the capital's network of clinics "ABC-Medicine" acquired 100% of the network of private clinics "Niarmedic" from the holding "Doctor Nearby." As part of the transaction, 13 multidisciplinary medical centers in Moscow and one clinic in Obninsk were transferred to the buyer. All institutions will operate under a single ABC-Medicine brand.

According to Daria Shubina, general director of the Eqiva consulting company, the transaction cost could be about 1.5 billion rubles. From her point of view, the acquisition will allow ABC Medicine to strengthen its position in the voluntary health insurance market by increasing the number of points for patients. According to Shubina, the operational efficiency of the acquired clinics may grow due to the effect of the scale of the combined network.

𝓲

Фото: Freepik

General Director of ABC-Medicine Artem Melikhov confirmed that the deal is aimed at expanding the volume of services and strengthening the territorial availability of clinics. According to him, the company's growth strategy combines the launch of its own branches, the acquisition of assets and the development of franchising. He added that the active expansion of the network began in 2024 with the opening of three new clinics in Moscow and the purchase of the centers "Child and Family," "Premier Medica" and "MRT24."

According to Maxim Chernin, general director of the Doctor Nearby holding, the sale corresponds to the company's strategy. Chernin said that in recent years, deep digitalization of clinics has been carried out, including the introduction of a unified medical information system and the creation of a digital platform. Thus, the obtained technological potential was transferred to the new owner.

Chernin also said that the holding plans to concentrate resources on the development of medical technologies, including the expansion of the digital health ecosystem, telemedicine and the creation of new products using artificial intelligence.^[1]

"Doctor Nearby" bought "Niarmedic"

On December 18, 2025 To Moscow , AFK System completed a deal to sell a 50% stake in the Niarmedic clinic network. The asset was acquired by the partner of the joint development organization - LLC Doctor nearby holding"." As a result, Doctor Nearby Holding became the sole owner, consolidating 100% of the network.

According to the press service of AFK Sistema, the corporation has implemented the goals set when entering the project as a financial investor with a minority stake. According to company representatives, the decision to exit corresponds to the strategy for optimizing the asset portfolio. For Doctor Nearby Holding, this transaction is also strategic, allowing you to focus network management and develop projects in the field of digital medicine.

𝓲

Фото: Freepik

As the CEO of Eqiva Daria Shubina noted back in June 2025, when selling such medical assets, the multiplier usually does not exceed 1-1.2 to annual revenue. Based on this, the expert estimated the capitalization of the entire network at up to 2.5 billion rubles.

In an interview with Vedomosti, Daria Shubina suggested that AFK Sistema could face difficulties when trying to sell only its stake in Niarmedic - Doctor Nearby. She explained that the main buyers in the market are current players who, as strategic investors, seek to acquire controlling stakes - from 50% and above.

As for potential buyers of the entire network, according to one of the interlocutors, Sheets"" among them may be Severgroup"." Alexey Mordashov Since 2018, the holding has owned the St. Petersburg network of Scandinavia clinics and, as the source notes, is considering buying assets to bring its medical business to the federal level.^{[2] [3]}

Appointment of Sergei Arabadzhyan as CEO

In early February 2025 "Niarmedic" , a new general director was appointed in the network of clinics. This position was taken by Sergei Arabadzhyan, who had previously worked in the company as deputy head for development. More here

2024: AFK Sistema became the 100% owner of the Niarmedic clinic network by buying out Sber's stake

PJSC AFK Sistema consolidated 100% shares in the Niarmedic group of companies, having bought out Sberbank's share in the pharmaceutical asset. The corporation announced this in April 2025, revealing the details of the transaction in the reporting for 2024.

According to Interfax, the deal to increase the share of AFK Sistema from 50% to 100% took place in November 2024. As a result, the company gained full control over the pharmaceutical manufacturer, which was previously accounted for as an investment in a joint venture.

𝓲

Фото: Freepik

The press service of AFK Sistema explained that this operation corresponds to the terms of the shareholder agreement concluded in the fall of 2021. According to the management of the corporation, Niarmedic Group of Companies has significant development potential, and the competencies of AFK Sistema in pharmaceuticals, medicine and biotechnology will significantly increase the shareholder value of the acquired company.

The initial transaction for the acquisition of Niarmedic Group of Companies took place in September 2021, when Sistema and Sber acquired a pharmaceutical asset for a symbolic amount of 1 ruble. At the same time, the net debt of the group of companies at the time of purchase amounted to ₽5,9 billion.

According to the reports of AFK Sistema, the corporation and its financial partner provided equal share financing in the amount of ₽1,2 billion to pay off part of the debt. In addition, the partners entered into an agreement, under the terms of which 3.5 years after the transaction, AFK receives the right to redeem Sberbank's share with the simultaneous transfer to the corporation of the rights of claim of the financial partner on a loan provided by Niarmedic Group of Companies in the amount of up to ₽2,8 billion.

Earlier, AFK Sistema and Sber acquired the Cypriot company Nearmedic International Limited through a joint venture - JSC New Investment Holding, in which AFK owned 50% + 1 share, and Sber - 50% -1^[4]

2021: New Investment Holding JSC bought Niarmedic for 5.9 billion rubles

On September 15, 2021, the sale of Niarmedic to AFK Sistema and Sberbank for 1 ruble was announced. The symbolic value of the transaction is due to the large debts of the pharmaceutical company - about 5.9 billion rubles.

Under the terms of the agreement, New Investment Holding JSC, owned by AFK Sistema and Sberbank, bought Nearmedic International Limited, which owns 100% of the authorized capital of Niarmedic Plus LLC, Niarmedic Pharma LLC and other companies operating in the fields of pharmaceuticals, biotechnology and medicine.

The agreement provides that AFK Sistema can buy a share of Sberbank and obtain the rights of the bank's claim on the loan, which was provided to Niarmedic, in the amount of up to 2.8 billion rubles. The maximum term of execution of the agreement is 3.5 years from the date of closing of the transaction.

AFK Sistema and Sberbank bought Niarmedic for 5.9 billion rubles

AFK Sistema President Vladimir Chirakhov, commenting on the deal, noted that Niarmedic has a development potential that can be implemented through restructuring and increased efficiency.

It is in this that AFK Sistema, as an investment company, has a powerful and proven expertise. Moreover, AFK Sistema has accumulated significant competencies in pharmaceuticals, medicine and biotechnology - all these areas are key for Niarmedic, he said, adding that in the near future it is planned to implement a plan to optimize Niarmedic's business, which is expected to increase the shareholder value of assets acquired under the transaction, and expand the production capabilities of Sistema.

By mid-September 2021, the Niarmedic group includes production sites in Obninsk and Mosalsk, a medical device factory in Italy and a network of medical clinics in Moscow, Obninsk and Ryazan.^[5]

2020

Association with the Center for Endosurgery and Lithotripsy

At the end of December 2020, it became known about the joining of the Center for Endosurgery and Lithotripsy (CELT) to the network of Niarmedic clinics, which, along with the Doctor Nearby network, is part of the joint Doctor Nearby Holding LLC. The financial component of the transaction was not disclosed. Read more here.

Creation of the company as a result of the merger of the Doctor Nearby and Niarmedic networks

In mid-July 2020, the Doctor Nearby and Niarmedic clinics completed the merger, which was announced a year earlier. As a result of the transaction, the shares of the combined company - United Company Niarmedic - Doctor Nearby LLC - were distributed between the shareholders of Doctor Nearby and Niarmedic in a ratio of 45% to 55%, respectively. Read more here.

2013

RUSNANO announced in December 2013 the successful withdrawal from the capital of NIARMEDIC PHARMA, a joint venture between RUSNANO and the Russian pharmaceutical company NIARMEDIC PLUS. RUSNANO's share in the authorized capital of the project company - 34.45% - was bought out for 2.3 billion rubles by the project applicant, NIARMEDIC PLUS LLC. RUSNANO's investment return (IRR) will be 41.1%.

RUSNANO investments in the amount of 1.3 billion rubles were primarily directed to the construction of the company's plant in the city of Obninsk, Kaluga Region. The total area of ​ ​ the complex, the commissioning of which is fully scheduled for 2014, will be 22 thousand square meters. The general contractor was FormaPharm Engineering Group, which has experience in the design and construction of more than a dozen modern pharmaceutical plants in Europe and Russia.

Notes